Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonoscopy | 14 | 2023 | 58 | 4.780 |
Why?
|
| Colonic Polyps | 4 | 2022 | 17 | 2.240 |
Why?
|
| Cathartics | 4 | 2018 | 11 | 2.230 |
Why?
|
| Adenoma | 4 | 2022 | 59 | 2.160 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 133 | 2.080 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 116 | 1.160 |
Why?
|
| Gastroenterology | 2 | 2018 | 14 | 0.740 |
Why?
|
| Oxytocin | 1 | 2021 | 5 | 0.740 |
Why?
|
| Colon | 2 | 2018 | 119 | 0.690 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 50 | 0.690 |
Why?
|
| Humans | 31 | 2023 | 26826 | 0.670 |
Why?
|
| Male | 21 | 2023 | 12869 | 0.650 |
Why?
|
| Esophageal Stenosis | 1 | 2018 | 3 | 0.640 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 23 | 0.620 |
Why?
|
| Colonic Diseases | 1 | 2018 | 10 | 0.620 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 19 | 0.620 |
Why?
|
| Liver Cirrhosis | 3 | 2018 | 67 | 0.620 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 8 | 0.610 |
Why?
|
| Duodenal Diseases | 1 | 2018 | 7 | 0.610 |
Why?
|
| Hydralazine | 1 | 2018 | 6 | 0.610 |
Why?
|
| Female | 19 | 2023 | 14462 | 0.600 |
Why?
|
| Veterans Health | 2 | 2016 | 6 | 0.600 |
Why?
|
| Duodenum | 1 | 2018 | 15 | 0.600 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 38 | 0.600 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2433 | 0.570 |
Why?
|
| Gastrointestinal Transit | 1 | 2016 | 8 | 0.560 |
Why?
|
| Narcotics | 1 | 2016 | 10 | 0.560 |
Why?
|
| Patient Compliance | 1 | 2017 | 75 | 0.550 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2014 | 39 | 0.540 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 87 | 0.540 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2015 | 130 | 0.530 |
Why?
|
| Liver Neoplasms | 3 | 2015 | 164 | 0.510 |
Why?
|
| Aged | 10 | 2018 | 5166 | 0.500 |
Why?
|
| Conscious Sedation | 1 | 2015 | 10 | 0.490 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 14 | 0.490 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 30 | 0.490 |
Why?
|
| Preoperative Care | 1 | 2015 | 76 | 0.480 |
Why?
|
| Butylscopolammonium Bromide | 1 | 2014 | 2 | 0.480 |
Why?
|
| Middle Aged | 12 | 2023 | 6817 | 0.470 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 207 | 0.460 |
Why?
|
| Image Enhancement | 1 | 2014 | 57 | 0.460 |
Why?
|
| Pain | 1 | 2016 | 252 | 0.460 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 102 | 0.450 |
Why?
|
| Hepatitis C | 2 | 2013 | 38 | 0.440 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 140 | 0.430 |
Why?
|
| Mental Disorders | 1 | 2014 | 103 | 0.420 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 14 | 0.420 |
Why?
|
| Needles | 1 | 2013 | 26 | 0.420 |
Why?
|
| Stress, Psychological | 1 | 2014 | 209 | 0.390 |
Why?
|
| Alanine Transaminase | 2 | 2018 | 25 | 0.390 |
Why?
|
| Video Recording | 1 | 2011 | 38 | 0.380 |
Why?
|
| Glycogen Storage Disease Type VII | 1 | 2011 | 2 | 0.380 |
Why?
|
| Mesenteric Veins | 1 | 2011 | 3 | 0.380 |
Why?
|
| Portal Vein | 1 | 2011 | 8 | 0.380 |
Why?
|
| Gastroscopy | 1 | 2011 | 7 | 0.370 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.370 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 98 | 0.350 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 17 | 0.350 |
Why?
|
| Catheterization | 1 | 2010 | 50 | 0.340 |
Why?
|
| Pancreatitis | 1 | 2010 | 36 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 84 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 58 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 276 | 0.290 |
Why?
|
| United States | 4 | 2017 | 2032 | 0.280 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 377 | 0.280 |
Why?
|
| Midazolam | 2 | 2018 | 8 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 507 | 0.270 |
Why?
|
| Comorbidity | 2 | 2018 | 252 | 0.270 |
Why?
|
| Fentanyl | 2 | 2018 | 31 | 0.270 |
Why?
|
| Risk Factors | 3 | 2018 | 2010 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2018 | 104 | 0.240 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 93 | 0.230 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 16 | 0.220 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 31 | 0.210 |
Why?
|
| Adult | 8 | 2023 | 7382 | 0.210 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 508 | 0.200 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 121 | 0.200 |
Why?
|
| Cecum | 1 | 2022 | 14 | 0.200 |
Why?
|
| Orexins | 1 | 2021 | 1 | 0.190 |
Why?
|
| Hypothalamus | 1 | 2021 | 29 | 0.180 |
Why?
|
| Veterans | 1 | 2022 | 66 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 357 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 284 | 0.180 |
Why?
|
| Eating | 1 | 2021 | 66 | 0.180 |
Why?
|
| Health Resources | 2 | 2017 | 18 | 0.180 |
Why?
|
| Electric Stimulation | 1 | 2021 | 253 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 472 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 545 | 0.160 |
Why?
|
| Diet | 1 | 2021 | 223 | 0.160 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2018 | 3 | 0.150 |
Why?
|
| Glucagon | 1 | 2018 | 11 | 0.150 |
Why?
|
| Diphenhydramine | 1 | 2018 | 3 | 0.150 |
Why?
|
| Medical Staff, Hospital | 1 | 2018 | 21 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 14 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 144 | 0.150 |
Why?
|
| Operative Time | 1 | 2018 | 40 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 29 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2018 | 230 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 4 | 0.140 |
Why?
|
| Rats | 1 | 2021 | 1545 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 13 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2017 | 53 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 6 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 445 | 0.140 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 10 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 218 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2018 | 204 | 0.140 |
Why?
|
| Cost Savings | 1 | 2016 | 19 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
| Age Factors | 1 | 2018 | 716 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 112 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 54 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.130 |
Why?
|
| Mass Screening | 1 | 2016 | 141 | 0.130 |
Why?
|
| Dextran Sulfate | 1 | 2015 | 9 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2014 | 700 | 0.120 |
Why?
|
| Stem Cells | 2 | 2015 | 113 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 93 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 131 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2015 | 115 | 0.120 |
Why?
|
| Colitis | 1 | 2015 | 53 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 650 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 116 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2014 | 1216 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 755 | 0.120 |
Why?
|
| Hepatorenal Syndrome | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hepatic Encephalopathy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2014 | 6 | 0.120 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 5 | 0.120 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 3 | 0.120 |
Why?
|
| Peritonitis | 1 | 2014 | 15 | 0.120 |
Why?
|
| Ascites | 1 | 2014 | 19 | 0.120 |
Why?
|
| Afghan Campaign 2001- | 1 | 2014 | 11 | 0.120 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2014 | 11 | 0.120 |
Why?
|
| Hyponatremia | 1 | 2014 | 16 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2018 | 2264 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 186 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2014 | 54 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2013 | 25 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 28 | 0.110 |
Why?
|
| Ribavirin | 1 | 2013 | 9 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 65 | 0.100 |
Why?
|
| Incidence | 1 | 2014 | 545 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2013 | 50 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 472 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2014 | 390 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 98 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 747 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2012 | 38 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2015 | 280 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 49 | 0.100 |
Why?
|
| Esophagus | 1 | 2012 | 69 | 0.100 |
Why?
|
| Time Factors | 2 | 2015 | 1562 | 0.100 |
Why?
|
| Animals | 3 | 2021 | 9960 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 21 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 140 | 0.090 |
Why?
|
| Bile Ducts | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cachexia | 1 | 2011 | 51 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Quality of Life | 1 | 2013 | 464 | 0.080 |
Why?
|
| Fibrosis | 1 | 2010 | 115 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2015 | 240 | 0.080 |
Why?
|
| Research Design | 1 | 2010 | 174 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 464 | 0.080 |
Why?
|
| Hepacivirus | 2 | 2018 | 46 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 445 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2016 | 857 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 2581 | 0.060 |
Why?
|
| Occult Blood | 1 | 2023 | 4 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2015 | 771 | 0.050 |
Why?
|
| Benchmarking | 1 | 2022 | 28 | 0.050 |
Why?
|
| Prognosis | 2 | 2014 | 759 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 87 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 910 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 4 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 20 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 18 | 0.040 |
Why?
|
| Bilirubin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2018 | 35 | 0.040 |
Why?
|
| Colorectal Surgery | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 11 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 39 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 18 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 11 | 0.030 |
Why?
|
| Efficiency | 1 | 2016 | 17 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 27 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 30 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 34 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 450 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 89 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 46 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 135 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 108 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 313 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 313 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 251 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 733 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 60 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 138 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 253 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 453 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 665 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 503 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 240 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 444 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 203 | 0.030 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 3 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2012 | 12 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 66 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 59 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 2012 | 20 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2012 | 20 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 442 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 26 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 739 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 509 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 82 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 408 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1259 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 35 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 76 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 324 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 151 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 980 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 137 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 646 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1344 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 4406 | 0.020 |
Why?
|